Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S W Tan

Showing results (281-290 of 317) with videos related to

Pageof 32
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive CohortRafal Dziadziuszko, Tony Mok, Solange Peters, et al.
The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
JCO Precision Oncology|October 14, 2022
Clinical and Genomic Features of <i>HER2</i> Exon 20 Insertion Mutations and Characterization of <i>HER2</i> Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung CancerAaron C Tan, Stephanie P L Saw, Jianbin Chen, et al.
Cancer|February 29, 2024
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancerAaron C Tan, Gillianne G Y Lai, Stephanie P L Saw, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2020
Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLCAaron C Tan, Amanda O L Seet, Gillianne G Y Lai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)Aaron C Tan, Bin-Chi Liao, Molly Li, et al.
JCO Global Oncology|August 22, 2022
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent ConsiderationsChristian Caglevic, Christian Rolfo, Ignacio Gil-Bazo, et al.
Nature Communications|September 7, 2017
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a timeShumei Chia, Joo-Leng Low, Xiaoqian Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2022
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trialF Griesinger, G Curigliano, M Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate CancerTanya Dorff, Lisa G Horvath, Karen Autio, et al.
Pageof 32

Showing results (281-290 of 317) with videos related to

Sort By:
Pageof 32
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive CohortRafal Dziadziuszko, Tony Mok, Solange Peters, et al.
The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
JCO Precision Oncology|October 14, 2022
Clinical and Genomic Features of <i>HER2</i> Exon 20 Insertion Mutations and Characterization of <i>HER2</i> Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung CancerAaron C Tan, Stephanie P L Saw, Jianbin Chen, et al.
Cancer|February 29, 2024
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancerAaron C Tan, Gillianne G Y Lai, Stephanie P L Saw, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2020
Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLCAaron C Tan, Amanda O L Seet, Gillianne G Y Lai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)Aaron C Tan, Bin-Chi Liao, Molly Li, et al.
JCO Global Oncology|August 22, 2022
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent ConsiderationsChristian Caglevic, Christian Rolfo, Ignacio Gil-Bazo, et al.
Nature Communications|September 7, 2017
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a timeShumei Chia, Joo-Leng Low, Xiaoqian Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2022
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trialF Griesinger, G Curigliano, M Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate CancerTanya Dorff, Lisa G Horvath, Karen Autio, et al.
Pageof 32